Page 3 - Lupin Pharma
Lupin gets USFDA nod to market generic injection for kidney disease
The product is a generic version of Sanofi Genzyme's Hectorol injection
 "Lupin gets USFDA nod to market generic injection for kidney disease")
Lupin's Q2 net profit falls 41% to Rs 2.66 bn as sales slip in US
Net profit stood at Rs 2.68 billion compared to Rs 4.53 billion in the year-ago period
 "Lupin's Q2 net profit falls 41% to Rs 2.66 bn as sales slip in US")
Lupin Q2 net profit drops 41.5% to Rs 2.66 bn as sales slip in US
Lupin's North American sales stood at Rs 12.48 billion, down 8.25 per cent from Rs 13.61 billion in July-September period of the last fiscal
 "Lupin Q2 net profit drops 41.5% to Rs 2.66 bn as sales slip in US")
Lupin gets 5 observations from USFDA for Pithampur plant; shares fall 2%
The inspection at the site was conducted between October 8 and October 18, 2018
Lupin partners with Eli Lilly and Company to distribute diabetes injection
Lupin expects to make Aplevant available in India from October 2018, it said in a statement
 "Lupin partners with Eli Lilly and Company to distribute diabetes injection")
Lupin slips 5% as Q1 profit misses Street's estimate
The stock slipped 5% to Rs 821 on the BSE after the company reported 43% year-on-year drop in consolidated net profit at Rs 2.03 billion June quarter, hit by fall in sales in the US and Japan.
 "Lupin slips 5% as Q1 profit misses Street's estimate")
Despite positives, pharma major Lupin not a re-rating candidate
Analysts continue to be cautious, given the USFDA's warning letter to its plants at Goa and Indore, resolution of which is necessary to improve growth visibility
Lupin Pharmaceuticals eyes the next wave of growth in Japanese market
Lupin's Japan story assumes significance as it held on to the highly regulated market when most of its Indian peers quit
Lupin appoints Nicholas Hart as head of specialty biz in US
Hart will be based in Baltimore, Maryland in the US, and will report to Gupta
 "Lupin appoints Nicholas Hart as head of specialty biz in US")
Lupin Q4 net loss at Rs 7.83 billion due to one time write-off
Total revenue from operations stood at 40.33 billion as against 42.533 billion in the year-ago period, Lupin said in a regulatory filing
Lupin stock gains on EIR from USFDA, but not out of the woods yet
While approvals will help it launch its drugs in the US market, clearance for its various units removes a potential overhang
 "Lupin stock gains on EIR from USFDA, but not out of the woods yet")
Lupin launches generic Lodosyn tablets in US for Parkinson's disease
The product is the generic version of Aton Pharma Inc's Lodosyn tablets in the same strength
 "Lupin launches generic Lodosyn tablets in US for Parkinson's disease")
Lupin gets USFDA nod for contraceptive tablet 'Tydemy' for women
The approved Tydemy tablets are generic equivalents of Bayer HealthCare Pharmaceuticals Inc's Safyral tablets, Lupin said
 "Lupin gets USFDA nod for contraceptive tablet 'Tydemy' for women")
Lupin gets USFDA's final nod to market generic Tamiflu
Lupin shall commence promoting the product shortly, it added
Lupin Q3 net plunges 65% to Rs 2.2 bn on lower sales in North America
Lupin said its profit was hit by a foreign exchange loss of 821 million rupees compared to a gain of Rs 276 mllion a year earlier
 "Lupin Q3 net plunges 65% to Rs 2.2 bn on lower sales in North America")
Lupin receives USFDA nod to market Tamiflu capsules to treat influenza
Oseltamivir phosphate capsules are indicated for the treatment of influenza
 "Lupin receives USFDA nod to market Tamiflu capsules to treat influenza")
Lupin eyes share of $48 mn market with anti-infection capsule launch in US
Lupin shares were trading 2.47% up at Rs 899.15 apiece on BSE on Friday
